Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2024Clinical Lymphoma Myeloma & LeukemiaOpen Access

Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry

View Full Paper
Ask AI
Bookmark
Share

Authors

NGNilanjan GhoshJSJeff P. SharmanMGMeghan Gutierrez

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ghosh et al. (2024) studied this question.

synapsesocial.com/papers/68e59c4cb6db6435875366fahttps://doi.org/10.1016/j.clml.2024.05.009
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long‐Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib2026
  2. 2A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)2024 · 1 citations
  3. 3Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL2024 · 49 citations
  4. 4First-Line Treatment of Chronic Lymphocytic Leukemia in Italy: Real-World Evidence on Utilization, Outcomes, and Healthcare Costs2026
  5. 5Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL2025 · 40 citations